AVALO THERAPEUTICS, INC. Adjustments to Additional Paid in Capital, Warrant Issued
AVALO THERAPEUTICS, INC. (AVTX) reported Adjustments to Additional Paid in Capital, Warrant Issued of $3.64 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2025-03-20
- AVALO THERAPEUTICS, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2023-12-31 was $0.00.
- AVALO THERAPEUTICS, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2023-09-30 was $0.00.
- AVALO THERAPEUTICS, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2023-06-30 was $3.64M.
- AVALO THERAPEUTICS, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2021-12-31 was $0.00.
- AVALO THERAPEUTICS, INC. adjustments to additional paid in capital, warrant issued for fiscal 2023 was $3.64M.
- AVALO THERAPEUTICS, INC. adjustments to additional paid in capital, warrant issued for fiscal 2021 was $861.00K.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 6 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $3.64M derived: sum of 3 quarters · filed 2025-03-20 | $3.64M 10-K · filed 2025-03-20 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $3.64M derived: sum of 2 quarters · filed 2024-11-07 | $3.64M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $3.64M 10-Q · filed 2024-08-12 | $3.64M 10-Q · filed 2024-08-12 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $0.00 derived: sum of 2 quarters · filed 2023-03-29 | $861.00K derived: sum of 3 quarters · filed 2023-03-29 | $861.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $861.00K derived: sum of 2 quarters · filed 2022-11-07 | $861.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $861.00K 10-Q · filed 2022-08-04 | $861.00K 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $4.40M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |